Braeburn announced that Probuphine (buprenorphine) subdermal implant will be available in June to healthcare providers and patients.
Probuphine was approved by the Food and Drug Administration (FDA) on May 26, 2016 as the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically ≤8mg/day.
Probuphine is implanted subdermally in the inner side of the upper arm and is removed at the end of the treatment. Each implant contains the equivalent of buprenorphine 80mg. The 6-month treatment utilizes ProNeura, a drug delivery system that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance.
Data from preliminary pharmacoeconomic modeling showed that patients treated with Probuphine were predicted to have a 45% reduced likelihood of relapse, an 80% reduced likelihood of going to rehab, and a 98% reduced likelihood of pediatric exposure vs. patients treated with oral buprenorphine.
Probuphine, a CIII substance, will not be available at pharmacies. Instead, patients can only receive Probuphine from certified healthcare providers who have been trained to insert the implants through an in-office procedure. A specialty distributor will directly send Probuphine to trained and certified providers.
For more information call (866) 397-8939 or visit Probuphine.com.